Extended Use of Transdermal Norelgestromin/Ethinyl Estradiol: A Randomized Trial
Authors:
- Andrew M. KaunitzAKAndrew M. Kaunitz
- Katherine D. LaGuardiaKLKatherine D. LaGuardia
- Debra L. KarvoisDKDebra L. Karvois
- Alan C. FisherAFAlan C. Fisher
- Andrew J. FriedmanAFAndrew J. Friedman
- 1 June 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 105 (6) , 1389-1396
Abstract
To compare bleeding profiles and satisfaction among women using a norelgestromin/ethinyl estradiol (E2) transdermal contraceptive patch in an extended regimen to those among women using a traditional 28-day patch regimen. Healthy, regularly menstruating women (N = 239) were randomly assigned (2:1 ratio) to receive the norelgestromin/ethinyl E2 transdermal patch in an extended regimen (weekly application for 12 consecutive weeks, 1 patch-free week, and 3 more consecutive weekly applications, n = 158) or a cyclic regimen (4 consecutive cycles of 3 weekly applications and 1 patch-free week, n = 81). Subjects recorded bleeding data daily and completed satisfaction questionnaires. Subjects and investigators provided overall assessments of the regimens. Extended use of the norelgestromin/ethinyl E2 transdermal patch resulted in fewer median bleeding days (6 compared with 14, P < .001), bleeding episodes (1 compared with 3, P < .001), and bleeding or spotting episodes (2 compared with 3, P < .001) compared with cyclic use during days 1-84; median numbers of bleeding or spotting days were similar between regimens (14 compared with 16, P = .407) during this time. Extended use delayed median time to first bleeding to 54 days compared with 25 days with cyclic (P < .001). Subjects were highly satisfied with both regimens. Although not statistically significant, slightly more adverse events were reported with the extended than with the 28-day regimen. Compared with cyclic use, extended use of the norelgestromin/ethinyl E2 transdermal patch delayed menses and resulted in fewer bleeding days. This regimen may represent a useful alternative for women who prefer fewer episodes of withdrawal bleeding.Keywords
This publication has 19 references indexed in Scilit:
- A multicenter, randomized study of an extended cycle oral contraceptiveContraception, 2003
- Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial1 , *1Obstetrics & Gynecology, 2001
- The Debate regarding Continuous Use of Oral ContraceptivesAnnals of Pharmacotherapy, 2001
- Menstruation: choosing whether … and whenContraception, 2000
- Nuisance or natural and healthy: should monthly menstruation be optional for women?The Lancet, 2000
- Hormone withdrawal symptoms in oral contraceptive usersObstetrics & Gynecology, 2000
- Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy useContraception, 1999
- Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptomsObstetrics & Gynecology, 1997
- Long-interval treatment regimen with a desogestrel-containing oral contraceptiveContraception, 1993
- Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen.BMJ, 1977